GSK Investigational Site

Loxahatchee Groves, Florida 33470-9272

1 studies enrolling now · 10 studies all time

What they study most

Asthma, Epilepsy, Partial, Migraine Disorders, Pulmonary Disease, Chronic Obstructive, Seizure, Absence

Studies at this site

• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) — Recruiting now
• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) — Completed
• Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year — Completed
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures — Completed
• Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy — Completed